They included a variant discovered in our breast cancer-specific analysis, rs143745791 (NCBP1, OR [95% CI] = 5.95 [2.79, 12.67], p = 3.76 × 10−6), for which 16.2% of carriers, restricted to cases, had a breast and cervical cancer diagnosis, and a variant discovered in our urinary bladder cancer-specific analysis, rs141647689 (SDK1, OR [95% CI] = 9.29 [3.63, 23.80], p = 3.45 × 10−6), for which 14.3% of carriers also had prostate cancer (Fig. 2). This evidence concerns the gene SDK1 and breast cancer.